ReviewJournal of immunology research2014
Use of autoantibodies to detect the onset of breast cancer.
Review in Journal of immunology research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Correlation of Anti-TULP1 Autoantibodies with Breast Cancer and Autoimmune Retinopathy.International journal of molecular sciences · 2025Article
- The RELT Family of Proteins: An Increasing Awareness of Their Importance for Cancer, the Immune System, and Development.Biomedicines · 2023Review
- Cancer Is Associated with the Emergence of Placenta-Reactive Autoantibodies.Biomedicines · 2023Article
- Six autoantibodies as potential differential biomarkers of hepatocellular carcinoma vs. liver cirrhosis and chronic hepatitis: A prospective multi-institutional study.Oncology letters · 2022Article
- Review
- Establishment and validation of an immunodiagnostic model for prediction of breast cancer.Oncoimmunology · 2020Article
- The Construction of Bone Metastasis-Specific Prognostic Model and Co-expressed Network of Alternative Splicing in Breast Cancer.Frontiers in cell and developmental biology · 2020Article
- Profiling of Naturally Occurring Antibodies to the Thomsen-Friedenreich Antigen in Health and Cancer: The Diversity and Clinical Potential.BioMed research international · 2020Review
- Serum anti-GAPDH autoantibody levels reflect the severity of cervical lesions: A potential serum biomarker for cervical cancer screening.Oncology letters · 2019Article
- Autoantibodies as Potential Biomarkers in Breast Cancer.Biosensors · 2018Review
- Developments in Point-of-Care Diagnostic Technology for Cancer Detection.Diagnostics (Basel, Switzerland) · 2018Review
- Longitudinal autoantibody responses against tumor-associated antigens decrease in breast cancer patients according to treatment modality.BMC cancer · 2018Article
- The Thomsen-Friedenreich Antigen-Specific Antibody Signatures in Patients with Breast Cancer.BioMed research international · 2018Article
- Tumor-associated autoantibodies are useful biomarkers in immunodiagnosis of α-fetoprotein-negative hepatocellular carcinoma.World journal of gastroenterology · 2017Article
- Prospective evaluation of 64 serum autoantibodies as biomarkers for early detection of colorectal cancer in a true screening setting.Oncotarget · 2016Article
- Article
- Autoantibodies against tumor-associated antigens for detection of hepatocellular carcinoma.World journal of hepatology · 2015Review
- An Analysis of Immunoreactive Signatures in Early Stage Hepatocellular Carcinoma.EBioMedicine · 2015Article
- Investigation of circulating antibodies to ANXA1 in breast cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The widespread use of screening mammography has resulted in increased detection of early-stage breast disease, particularly for in situ carcinoma and early-stage breast cancer. However, the majority of women with abnormalities noted on screening mammograms are not diagnosed with cancer because of several factors, including radiologist assessment, patient age, breast density, malpractice concerns, and quality control procedures. Although magnetic resonance imaging is a highly sensitive detection tool that has become standard for women at very high risk of developing breast cancer, it lacks sufficient specificity and costeffectiveness for use as a general screening tool. Therefore, there is an important need to improve screening and diagnosis of early-invasive and noninvasive tumors, that is, in situ carcinoma. The great potential for molecular tools to improve breast cancer outcomes based on early diagnosis has driven the search for diagnostic biomarkers. Identification of tumor-specific markers capable of eliciting an immune response in the early stages of tumor development seems to provide an effective approach for early diagnosis. The aim of this review is to describe several autoantibodies identified during breast cancer diagnosis. We will focus on these molecules highlighted in the past two years and discuss the potential future use of autoantibodies as biomarkers of early-stage breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.